Millennium Management LLC Decreases Holdings in CureVac (NASDAQ:CVAC)

Millennium Management LLC decreased its position in shares of CureVac (NASDAQ:CVAC - Free Report) by 31.9% in the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,647,037 shares of the company's stock after selling 771,136 shares during the quarter. Millennium Management LLC owned approximately 0.74% of CureVac worth $5,616,000 at the end of the most recent quarter.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Jump Financial LLC bought a new position in shares of CureVac during the 4th quarter worth $55,000. D. E. Shaw & Co. Inc. bought a new position in shares of CureVac during the 4th quarter worth $66,000. XTX Topco Ltd grew its stake in shares of CureVac by 90.2% during the 4th quarter. XTX Topco Ltd now owns 24,365 shares of the company's stock worth $83,000 after acquiring an additional 11,553 shares during the period. Barclays PLC grew its stake in shares of CureVac by 51.8% during the 4th quarter. Barclays PLC now owns 34,836 shares of the company's stock worth $118,000 after acquiring an additional 11,890 shares during the period. Finally, Signaturefd LLC grew its stake in shares of CureVac by 29.2% during the 4th quarter. Signaturefd LLC now owns 36,140 shares of the company's stock worth $123,000 after acquiring an additional 8,170 shares during the period. Institutional investors own 17.26% of the company's stock.

Analyst Ratings Changes

Several brokerages have commented on CVAC. UBS Group cut their target price on CureVac from $13.00 to $12.00 and set a "buy" rating for the company in a research note on Wednesday, April 30th. JMP Securities restated a "market outperform" rating and issued a $10.00 target price on shares of CureVac in a research note on Wednesday.

CureVac Price Performance

NASDAQ CVAC traded down $0.10 during trading hours on Friday, hitting $4.53. The company had a trading volume of 853,039 shares, compared to its average volume of 739,127. CureVac has a 52 week low of $2.37 and a 52 week high of $5.28. The firm has a 50 day simple moving average of $3.38 and a 200 day simple moving average of $3.35. The company has a debt-to-equity ratio of 0.05, a quick ratio of 6.19 and a current ratio of 6.20. The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of 8.24 and a beta of 2.43.

CureVac (NASDAQ:CVAC - Get Free Report) last issued its earnings results on Thursday, May 22nd. The company reported ($0.24) EPS for the quarter, missing the consensus estimate of ($0.16) by ($0.08). CureVac had a return on equity of 21.98% and a net margin of 20.72%. The company had revenue of $0.94 million during the quarter, compared to the consensus estimate of $4.27 million. Equities research analysts expect that CureVac will post 0.72 earnings per share for the current year.

CureVac Company Profile

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.